Literature DB >> 6541693

Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.

D Collen, J M Stassen, B J Marafino, S Builder, F De Cock, J Ogez, D Tajiri, D Pennica, W F Bennett, J Salwa.   

Abstract

Human tissue-type plasminogen activator (t-PA), obtained by expression in mammalian cells of recombinant DNA coding for the entire sequence of t-PA (rt-PA), was compared with natural activator from melanoma cell culture (mt-PA). In an in vitro system, composed of [125I]fibrinogen-labeled plasma clot suspended in circulating human plasma, rt-PA and mt-PA caused a very similar dose-related degree of fibrinolysis without causing extensive fibrinolytic activation and fibrinogen breakdown in the surrounding plasma. Urokinase only induced fibrinolysis at a 5- to 10-fold higher concentration and in association with extensive fibrinogenolysis. Intravenous injection of mixtures of labeled (0.4 microCi/kg) and unlabeled (2000 I.U./kg) mt-PA or rt-PA resulted in a rapid but similar disappearance of activity from plasma (T1/2 of 3 min) and specific accumulation of tracer in the liver. In rabbits with experimental jugular vein thrombosis, rt-PA and mt-PA caused a very similar dose-dependent thrombolysis without causing substantial systemic activation of the fibrinolytic system and fibrinogenolysis. Urokinase induced significant thrombolysis only at a 10-fold higher dose and this was associated with systemic fibrinolytic activation. Infusion of 96,000 I.U./kg (approximately equal to 1 mg/kg) of mt-PA or rt-PA over 4 hr induced approximately 70% lysis, whereas a 10-fold higher dose of urokinase yielded 35 to 40% lysis. Two subfractions of rt-PA differing in the extent of glycosylation had very similar thrombolytic properties. It is concluded that the potentially more readily available rt-PA could constitute a specific, fibrin-selective thrombolytic agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541693

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

3.  Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.

Authors:  N Baziuk; T Fang; G A Peyman; C M Gremillion
Journal:  Int Ophthalmol       Date:  1991-03       Impact factor: 2.031

4.  Presence and transcription of intracisternal A-particle-related sequences in CHO cells.

Authors:  K P Anderson; Y S Lie; M A Low; S R Williams; E H Fennie; T P Nguyen; F M Wurm
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 5.  Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction?

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

Review 6.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

7.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

8.  Tissue-type plasminogen activator. Therapeutic potential in thrombotic disease states.

Authors:  D Collen
Journal:  Drugs       Date:  1986-01       Impact factor: 9.546

9.  Chinese hamster ovary cells contain transcriptionally active full-length type C proviruses.

Authors:  Y S Lie; E M Penuel; M A Low; T P Nguyen; J O Mangahas; K P Anderson; C J Petropoulos
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

Review 10.  Pharmacologic reperfusion therapy for acute myocardial infarction.

Authors:  Harry C Lowe; Briain D Mac Neill; Frans Van de Werf; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.